Skip to content

Clinton Foundation secures price cuts for efavirenz, abacavir and rapid HIV tests

Roche to share know-how in making protease inhibitors with poorest countries

ICAAC: Switch from AZT or d4T to tenofovir may improve blood fat levels

ICAAC: Switching from Combivir to Truvada has benefits for treatment-experienced patients

Treatment interruption study stopped after excess number of AIDS events seen in people taking treatment breaks

Two integrase inhibitors now making progress in clinical trials

Gilead and BMS to seek regulatory approval for efavirenz, Truvada coformulation

Study finds antiretroviral therapy cost-effective in South African setting

Clinical and immunological benefits lasting at least three years reported by large Kenyan antiretroviral programme